Feds push big Medicare formulary

The federal government is pressing private insurers offering a new drug benefit to include a long list of pharmaceuticals to their formularies. The result will likely be a wider choice of drugs than what is now available to many people in a private health plan, and some insurers are beginning to worry that the government's insistence on a broad drug package may force the cost of the program out of control. The drug benefit was originally advertised at a cost of $395 billion over 10 years, which was later raised to $534 billion. The Congressional Budget Office later revised that figure upward after accounting for the administration's formulary requirements.

- read this article from The New York Times for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.